P00734 (THRB_HUMAN) Homo sapiens (Human)
Prothrombin UniProtKBInterProSTRINGInteractive Modelling
622 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
464 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Cryo-em structure of human prothrombin:prothrombinase at 4.1 Angstrom resolution |
Heteromer P00742; P12259; | |||||
| Assess | ||||||
| Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human ppack… |
Heteromer | 1×0G7; | ||||
| Assess | ||||||
| Crystal Structure of the Heparin Cofactor II-S195A Thrombin Complex |
Heteromer P05546; | 1×NAG; 1×NA; 5×MPD; 2×NAG; | ||||
| Assess | ||||||
| 2.1 Angstrom structure of a nonproductive complex between antithrombin, synthetic heparin mimetic S… |
Heteromer P01008; | 2×NAG; 1×GU3; 1×NAG; 1×NAG; 12×GOL; 6×SO4; 1×NAG; | ||||
| Assess | ||||||
| 1.6 A structure of the PCI-thrombin-heparin complex |
Heteromer Q9N2I2; | 1×NAG; 1×SGN; 3×SO4; 5×GOL; | ||||
| Assess | ||||||
| Crystal Structure of Native S195A Thrombin with an Unoccupied Active Site |
Heteromer | 1×NAG; 1×NA; 4×GOL; 2×ACY; | ||||
| Assess | ||||||
| Crystal Structure of Na-free Thrombin in Complex with Thrombomodulin |
Heteromer P07204; | 7×SO4; 1×CA; | ||||
| Assess | ||||||
| 2.5A Crystal Structure of the Antithrombin-Thrombin-Heparin Ternary Complex |
Heteromer P01008; | 1×NAG; 1×GU3; 1×NAG; 1×NAG; 8×MPD; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of thrombin mutant W215A/E217A fused to EGF456 of thrombomodulin via a 31-residue… |
Heteromer P07204; | 1×NAG; 1×0G6; 1×K; 1×NA; 2×NAG; | ||||
| Assess | ||||||
| Crystal structure of human thrombin mutant S195A in complex with the extracellular fragment of huma… |
Heteromer P25116; | 1×NAG; 1×NA; 1×GOL; | ||||
| Assess | ||||||
| Crystal structures of protease nexin-1 in complex with S195A thrombin |
Heteromer P07093; | 3×ACT; 1×CA; 1×NA; | ||||
| Assess | ||||||
| Human thrombin mutant C191A-C220A in complex with the inhibitor PPACK |
Heteromer | 3×ZN; 1×0G6; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of thrombin bound to the extracellular fragment of PAR1 |
Heteromer P25116; | 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of thrombin mutant S195T bound with PPACK |
Heteromer | 1×0G6; 1×MES; 2×GOL; 1×NA; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of the thrombin mutant G193P bound to PPACK |
Heteromer | 3×ZN; 1×0G6; 1×NAG; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of the thrombin mutant G193A bound to PPACK |
Heteromer | 4×ZN; 1×0G6; 1×NAG; 1×NA; | ||||
| Assess | ||||||
| Tsetse thrombin inhibitor in complex with human alpha-thrombin - orthorhombic form at 12keV |
Heteromer O97373; | 1×NAG; 1×GOL; 1×NA; | ||||
| Assess | ||||||
| STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI… |
Heteromer P01050; | 1×NA; 1×CA; | ||||
| Assess | ||||||
| STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI… |
Heteromer P28504; | 1×NA; 1×CA; 1×ESI; | ||||
| Assess | ||||||
| Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine P… |
Heteromer P28504; | 1×NA; 1×696; | ||||
| Assess | ||||||
| Crystal structure of human alpha-thrombin*RWJ-51438 complex at 1.7 A |
Heteromer P28504; | 1×1Z0; 1×NAG; 2×NA; | ||||
| Assess | ||||||
| RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
Heteromer P28504; | 1×ZN; 1×NA; 1×BAI; | ||||
| Assess | ||||||
| RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
Heteromer P28504; | 3×ZN; 1×NA; 1×BAH; | ||||
| Assess | ||||||
| Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and … |
Heteromer P01050; | 1×NAG; 1×4ND; | ||||
| Assess | ||||||
| STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI… |
Heteromer P28504; | 1×NA; 1×BEN; | ||||
| Assess | ||||||
| Crystal structure of thrombin bound to an exosite 1-specific IgA Fab |
Heteromer | 1×NAG; 1×NAG; 3×PEG; 5×PO4; 1×CIT; 1×NA; 1×0G6; | ||||
| Assess | ||||||
| THE REFINED 1.9 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: INTERACTION WITH D-PHE-PRO-ARG… |
Heteromer | 1×0G6; | ||||
| Assess | ||||||
| RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES |
Heteromer P28504; | 2×ZN; 1×NA; 1×BAB; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D-PHE-PRO-AZALYS-ONP |
Heteromer P01050; | 1×NAG; 1×AZL; | ||||
| Assess | ||||||
| THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVA… |
Heteromer P28505; | 1×NAG; | ||||
| Assess | ||||||
| ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N-DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE |
Heteromer P01050; | 1×NAG; 2×IN2; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO-AZALYS-ONP |
Heteromer P01050; | 1×NAG; 1×ALZ; | ||||
| Assess | ||||||
| Novel Covalent Active Site Thrombin Inhibitors |
Heteromer P01050; | 1×166; | ||||
| Assess | ||||||
| Structure of thrombin inhibited by AERUGINOSIN298-A from a BLUE-GREEN ALGA |
Heteromer P09945; | 1×NA; | ||||
| Assess | ||||||
| SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES. |
Heteromer | 1×NA; 1×IH2; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and a modified thrombin binding aptamer… |
Heteromer | 1×0G6; 1×NAG; 1×NA; 1×K; | ||||
| Assess | ||||||
| STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN |
Heteromer P28507; | |||||
| Assess | ||||||
| NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS |
Heteromer P01050; | 1×157; | ||||
| Assess | ||||||
| Novel Covalent Active Site Thrombin Inhibitors |
Heteromer P01050; | 1×GR1; | ||||
| Assess | ||||||
| Novel Covalent Active Site Thrombin Inhibitors |
Heteromer P01050; | 1×167; | ||||
| Assess | ||||||
| Human alpha thrombin inhibited by RPPGF and hirugen |
Heteromer P01042; P28504; | |||||
| Assess | ||||||
| Crystal Structure of the Complex of Platelet Receptor GPIb-alpha and Human alpha-Thrombin |
Heteromer P07359; | 1×NAG; 1×CL; 1×NAG; | ||||
| Assess | ||||||
| THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVA… |
Heteromer P28507; | 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of the thrombin-thrombomodulin complex |
Heteromer P07204; | 1×FMT; 1×CA; 2×NA; 1×NAG; 4×0GJ; | ||||
| Assess | ||||||
| THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVA… |
Heteromer | 1×0G6; 1×NAG; | ||||
| Assess | ||||||
| THE INTERACTION OF THROMBIN WITH FIBRINOGEN: A STRUCTURAL BASIS FOR ITS SPECIFICITY |
Heteromer P02671; P28506; | |||||
| Assess | ||||||
| SER195ALA MUTANT OF HUMAN THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A (7-16) |
Heteromer P02671; | |||||
| Assess | ||||||
| 2.5A Structure of Anticoagulant Thrombin Variant E217K |
Heteromer | 1×NAG; 1×NAG; 3×PO4; 6×GOL; | ||||
| Assess | ||||||
| ACTIVE SITE MIMETIC INHIBITION OF THROMBIN |
Heteromer P09945; | |||||
| Assess | ||||||
| THE STRUCTURE OF ALPHA-THROMBIN INHIBITED BY A 15-MER SINGLE-STRANDED DNA APTAMER |
Heteromer | 1×0G7; | ||||
| Assess | ||||||
| Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor |
Heteromer Q25163; | |||||
| Assess | ||||||
| Mechanism of Sulfotyrosine-Mediated Glycoprotein Ib Interaction with Two Distinct alpha-Thrombin Si… |
Heteromer P07359; | 1×NAG; 1×0G7; 1×NAG; | ||||
| Assess | ||||||
| Non-cleavable tsetse thrombin inhibitor in complex with human alpha-thrombin |
Heteromer O97373; | 1×NAG; 1×NA; 1×GOL; | ||||
| Assess | ||||||
| HUMAN ALPHA THROMBIN COMPLEXED WITH ANOPHELES GAMBIAE cE5 ANTICOAGULANT |
Heteromer Q7Q3R9; | 1×NAG; 1×NA; | ||||
| Assess | ||||||
| Low-salt crystal structure of a thrombin-GpIbalpha peptide complex |
Heteromer P07359; | 2×GOL; 1×0G6; 1×NA; | ||||
| Assess | ||||||
| Tsetse thrombin inhibitor in complex with human alpha-thrombin - orthorhombic form at 7keV |
Heteromer O97373; | 2×GOL; 1×NAG; 1×NA; | ||||
| Assess | ||||||
| X-ray structure of the complex between human thrombin and the TBA deletion mutant lacking thymine 3… |
Heteromer | 1×NAG; 1×0G6; 1×NA; 1×K; | ||||
| Assess | ||||||
| A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK … |
Heteromer P28504; | 1×ZN; 1×CA; 1×NA; 1×BMZ; | ||||
| Assess | ||||||
| Crystal structure of thrombin mutant S195T (free form) |
Heteromer | 1×K; 3×GOL; | ||||
| Assess | ||||||
| Crystal structure of human thrombin mutant I16T |
Heteromer | 2×GOL; | ||||
| Assess | ||||||
| SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN |
Heteromer P28504; | 1×NA; 1×130; | ||||
| Assess | ||||||
| Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala1… |
Heteromer P28504; | 1×NA; 1×CA; 1×CR9; | ||||
| Assess | ||||||
| A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK … |
Heteromer P28504; | 1×NA; 1×BMZ; | ||||
| Assess | ||||||
| A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK … |
Heteromer P28504; | 3×ZN; 1×NA; 1×CA; 1×121; | ||||
| Assess | ||||||
| A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK … |
Heteromer P28504; | 1×NA; 1×120; | ||||
| Assess | ||||||
| Human alpha-thrombin complexed with N-(methylsulfonyl)-D-phenylalanyl-N-((1-carbamimidoyl-4-piperid… |
Heteromer P01050; | 1×0BM; | ||||
| Assess | ||||||
| Madanins (MEROPS I53) are cleaved by thrombin and factor Xa |
Heteromer Q86FP9; | 1×NAG; 1×NA; 2×SO4; | ||||
| Assess | ||||||
| Crystal structure for human thrombin mutant D189A |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| THROMBIN INHIBITOR WITH A RIGID TRIPEPTIDYL ALDEHYDES |
Heteromer P01050; | 1×0IT; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of thrombin bound to heparin |
Heteromer | 1×IDS; 1×NAG; 1×SGN; 2×NAG; 1×NAG; 4×0G6; 4×NA; 8×GOL; | ||||
| Assess | ||||||
| SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES. |
Heteromer P28504; | 1×NA; 1×IH1; | ||||
| Assess | ||||||
| STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN |
Heteromer P28504; | |||||
| Assess | ||||||
| STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR |
Heteromer | |||||
| Assess | ||||||
| Crystal structure for the complex of thrombin mutant D102N and hirudin |
Heteromer P01050; | 1×NA; 1×NAG; 3×ACT; | ||||
| Assess | ||||||
| STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBIT… |
Heteromer P28504; | |||||
| Assess | ||||||
| THE REFINED STRUCTURE OF THE HIRUDIN-THROMBIN COMPLEX |
Heteromer P09945; | 1×NAG; | ||||
| Assess | ||||||
| X-RAY STRUCTURE OF THE COMPLEX OF HUMAN ALPHA THROMBIN WITH THE INHIBITOR SDZ 229-357 |
Heteromer | 1×R56; | ||||
| Assess | ||||||
| Crystal structure of thrombin in complex with fibrinogen gamma' peptide |
Heteromer P02679; | 2×NA; 1×NAG; | ||||
| Assess | ||||||
| STRUCTURE OF A RETRO-BINDING PEPTIDE INHIBITOR COMPLEXED WITH HUMAN ALPHA-THROMBIN |
Heteromer P28509; | 1×0E7; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and the duplex/quadruplex aptamer M08s-… |
Heteromer | 1×NAG; 1×0G6; 2×NA; | ||||
| Assess | ||||||
| Thrombin in Complex with a D-Phe-Pro-p-phenol derivative |
Heteromer P09945; | 1×NAG; 2×MD8; 1×PO4; 2×NA; | ||||
| Assess | ||||||
| Thrombin in complex with D-Phe-Pro-2-chlorothiophen derivative (16e) |
Heteromer P09945; | 1×EDO; 2×NA; 1×PO4; 1×NAG; 2×OQZ; 1×DMS; | ||||
| Assess | ||||||
| Thrombin in complex with (S)-(4-chloro-2-((1-(5-methyl-1H-pyrrole-2-carbonyl)pyrrolidine-2-carboxam… |
Heteromer P01050; | 1×MG; 1×GOL; 1×NAG; 1×45S; | ||||
| Assess | ||||||
| THROMBIN INHIBITOR FROM THEONALLA, CYCLOTHEANAMIDE-BASED MACROCYCLIC TRIPEPTIDE MOTIF |
Heteromer P01050; | 1×1ZV; | ||||
| Assess | ||||||
| thrombin inhibitors |
Heteromer P09945; | 1×NA; 1×C7M; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITO… |
Heteromer P28504; | |||||
| Assess | ||||||
| Active site thrombin inhibitors |
Heteromer P01050; | 1×L02; 3×DMS; | ||||
| Assess | ||||||
| Crystal structure of thrombin-avathrin complex |
Heteromer Q6F3E8; | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITO… |
Heteromer P09944; | |||||
| Assess | ||||||
| Human alpha-thrombin with 180- and 220- loops replaced with homologous loops from protein C |
Heteromer | 5×SO4; 1×NAG; 1×GOL; | ||||
| Assess | ||||||
| thrombin inhibitors |
Heteromer P09945; | 1×NA; 1×DMS; 1×C2A; | ||||
| Assess | ||||||
| thrombin inhibitors |
Heteromer P09945; | 2×DMS; 1×NA; 1×C5M; | ||||
| Assess | ||||||
| thrombin inhibitors |
Heteromer P09945; | 3×DMS; 1×NA; 1×C3M; | ||||
| Assess | ||||||
| Active site thrombin inhibitors |
Heteromer P09945; | 1×L03; 3×DMS; | ||||
| Assess | ||||||
| thrombin inhibitors |
Heteromer P09945; | 2×DMS; 1×NA; 1×C4M; | ||||
| Assess | ||||||
| thrombin inhibitors |
Heteromer P09945; | 1×DMS; 1×NA; 1×C1M; | ||||
| Assess | ||||||
| THE STRUCTURE OF A COMPLEX OF RECOMBINANT HIRUDIN AND HUMAN ALPHA-THROMBIN |
Heteromer P09945; | |||||
| Assess | ||||||
| MOLECULAR BASIS FOR THE INHIBITION OF HUMAN ALPHA-THROMBIN BY THE MACROCYCLIC PEPTIDE CYCLOTHEONAMI… |
Heteromer P09945; | |||||
| Assess | ||||||
| Orally active thrombin inhibitors |
Heteromer | 1×3SP; | ||||
| Assess | ||||||
| Human Thrombin complexed with a d-Phe-Pro-Arg-type Inhibitor and a C-terminal Hirudin derived exo-s… |
Heteromer | 1×163; | ||||
| Assess | ||||||
| Orally Active Thrombin Inhibitors in Complex with Thrombin Inh12 |
Heteromer | 1×NA9; | ||||
| Assess | ||||||
| orally active thrombin inhibitors in complex with thrombin and an exosite decapeptide |
Heteromer | 1×N12; | ||||
| Assess | ||||||
| ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE |
Heteromer P01008; | 1×YYB; 3×NAG; 1×GU4; | ||||
| Assess | ||||||
| Thrombin in complex with 5-chlorothiophene-2-carboxamide |
Heteromer P09945; | 2×NA; 1×PO4; 2×DMS; 3×GOL; 2×EDO; 1×FQI; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of human thrombin mutant N143P in E:Na+ form |
Heteromer | 4×NA; 4×NO3; 2×NAG; 2×GOL; | ||||
| Assess | ||||||
| Structural basis of thrombin mediated factor V activation: essential role of the hirudin-like seque… |
Heteromer P12259; | 3×NA; 1×0G6; 1×NAG; 3×CL; 1×MPD; | ||||
| Assess | ||||||
| Structure of human thrombin with residues 145-150 of murine thrombin. |
Heteromer | 1×NAG; 2×NA; | ||||
| Assess | ||||||
| Thrombin in complex with D-Phe-Pro-2-chlorofuran derivative (13l) |
Heteromer P09945; | 2×NA; 1×NAG; 3×DMS; 1×QKE; | ||||
| Assess | ||||||
| Tsetse thrombin inhibitor in complex with human alpha-thrombin - tetragonal form at 12.7keV |
Heteromer O97373; | 1×NAG; 1×NA; | ||||
| Assess | ||||||
| Structure of Thrombin Bound to the Inhibitor FM19 |
Heteromer | 3×IOD; 1×NA; 2×GOL; | ||||
| Assess | ||||||
| Thrombin-RNA aptamer complex |
Heteromer | 1×0G6; 1×NAG; 4×EDO; 2×GOL; 1×CA; 1×MRD; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of an RNA aptamer bound to human thrombin |
Heteromer | 3×PEG; 1×0G6; 2×MG; 1×P6G; 6×ACY; | ||||
| Assess | ||||||
| Crystal structure of thrombin bound to the activation domain QEDQVDPRLIDGKMTRRGDS of protein C |
Heteromer P04070; | 1×NA; 1×PEG; 1×ACT; | ||||
| Assess | ||||||
| THROMBIN INHIBITOR COMPLEX |
Heteromer P28504; | 1×R11; | ||||
| Assess | ||||||
| Thrombin in complex with inhibitor |
Heteromer P01050; | 1×NAG; 1×MEL; 2×NA; | ||||
| Assess | ||||||
| THROMBIN INHIBITOR COMPLEX |
Heteromer P28504; | 1×T87; | ||||
| Assess | ||||||
| The allosteric E*-E equilibrium is a key property of the trypsin fold |
Heteromer | 6×IOD; 1×NAG; 1×CL; | ||||
| Assess | ||||||
| Thrombin inhibitor complex |
Heteromer P28504; | 1×C02; | ||||
| Assess | ||||||
| Staphylocoagulase-Thrombin Complex |
Heteromer Q846V4; | 1×0ZJ; 2×HG; 3×IMD; | ||||
| Assess | ||||||
| Staphylocoagulase-Prethrombin-2 complex |
Heteromer Q846V4; | 1×0ZJ; 2×HG; 3×IMD; | ||||
| Assess | ||||||
| Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding mechanism |
Heteromer Q9NJS1; | 1×NAG; 1×NA; | ||||
| Assess | ||||||
| Thrombin Inhibitor Complex |
Heteromer P28504; | 1×C24; | ||||
| Assess | ||||||
| Thrombin:suramin complex |
Heteromer | 1×SVR; | ||||
| Assess | ||||||
| Crystal structure of human thrombin mutant W215A/E217A in complex with the extracellular fragment o… |
Heteromer P25116; | 1×NAG; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-4-[(AMINOIMINOMETHYL)AMINO]-N-[[1-[3-HYDROXY-2-[(2-… |
Heteromer P01050; | 1×BM2; | ||||
| Assess | ||||||
| Crystal structure of human thrombin mutant D194A |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Tsetse thrombin inhibitor in complex with human alpha-thrombin - tetragonal form at 7keV |
Heteromer O97373; | 1×NAG; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and a pseudo-cyclic thrombin binding ap… |
Heteromer | 1×0G6; 1×NA; 1×LMR; 1×JL0; 1×JKR; 1×K; | ||||
| Assess | ||||||
| Crystal structure of the complex between thrombin and the central "E" region of fibrin |
Heteromer P02671; P02675; P02679; | 2×0G6; 2×PO4; | ||||
| Assess | ||||||
| Thrombin in complex with 3-chloro-benzamide |
Heteromer P09945; | 2×NA; 1×WCE; 2×DMS; 1×PO4; 2×GOL; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in complex with 1-amidinopiperidine |
Heteromer P09945; | 1×IOD; 3×GOL; 2×NA; 1×PO4; 3×DMS; 1×EDO; 1×MRZ; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in complex with 1-(2R)-2-amino-3-phenyl-propanoyl-N-(2, 5dichlorophenyl)methylpyrrolidine-… |
Heteromer P09945; | 2×NA; 1×N6L; 1×PO4; 1×GOL; 1×NAG; | ||||
| Assess | ||||||
| Human Thrombin in complex with MI003 |
Heteromer P09945; | 1×NAG; 1×S00; 1×PO4; 2×GOL; 2×NA; | ||||
| Assess | ||||||
| Thrombin in complex with ((4-chlorophenyl)sulfamoyl))diemethylamine |
Heteromer P09945; | 2×NA; 2×DMS; 1×PO4; 1×GOL; 1×Y4L; 1×NAG; | ||||
| Assess | ||||||
| Thrombin-hirugen binary complex at 1.26A resolution |
Heteromer P01050; | 1×NA; 1×CA; | ||||
| Assess | ||||||
| 4-chloro-benzamidine in complex with thrombin |
Heteromer | 2×NA; 1×DKQ; 3×DMS; 1×PO4; 1×GOL; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(4-carbamimidoylbenzyl)pyrroli… |
Heteromer P09945; | 1×NAG; 3×DMS; 1×PO4; 2×NA; 1×6OV; | ||||
| Assess | ||||||
| Human Thrombin In Complex With UBTHR104 |
Heteromer P09945; | 1×NAG; 1×B04; 1×PO4; 1×GOL; 2×NA; | ||||
| Assess | ||||||
| Human thrombin complexed with D-Phe-Pro-D-Arg-D-Thr |
Heteromer | 1×NAG; 1×NA; 1×IOD; 1×CL; 2×MRD; | ||||
| Assess | ||||||
| Thrombin Mutant A190S in complex with (S)-1-(D-phenylalanyl)-N-(4-carbamimidoylbenzyl)pyrrolidine-2… |
Heteromer P09945; | 5×GOL; 2×DMS; 1×PO4; 2×NA; 1×32U; | ||||
| Assess | ||||||
| Human Thrombin In Complex With UBTHR105 |
Heteromer P09945; | 1×NAG; 1×P05; 1×PO4; 3×GOL; 2×NA; | ||||
| Assess | ||||||
| Thrombin in Complex with a D-Phe-Pro-p-aminopyridine derivative |
Heteromer P09945; | 1×NAG; 1×J5K; 1×PO4; 1×GOL; 2×NA; | ||||
| Assess | ||||||
| Thrombin-hirugen-gw473178 ternary complex at 1.32A resolution |
Heteromer P01050; | 1×NA; 1×CA; 1×896; | ||||
| Assess | ||||||
| Thrombin in Complex with a D-Phe-Pro-2-aminopyridine derivative |
Heteromer P09945; | 1×NAG; 1×PO4; 1×GOL; 2×NA; 1×M6Q; | ||||
| Assess | ||||||
| Thrombin in complex with D-Phe-Pro-m-methoxybenzylamide derivative (16a) |
Heteromer P09945; | 1×PO4; 2×NA; 1×NAG; 1×GOL; 1×DPN; 1×PRO; 1×SZ4; | ||||
| Assess | ||||||
| Thrombin in complex with MI2105 |
Heteromer P09945; | 1×KDQ; 1×NAG; 1×PO4; 3×DMS; 2×NA; | ||||
| Assess | ||||||
| Human Thrombin in complex with MI354 |
Heteromer P09945; | 1×NAG; 2×S54; 1×PO4; 1×GOL; 2×NA; | ||||
| Assess | ||||||
| Thrombin in Complex with a D-Phe-Pro-p-benzylamine derivative |
Heteromer P09945; | 2×NA; 2×DMS; 1×K73; 6×GOL; 1×PO4; 1×NAG; | ||||
| Assess | ||||||
| Thrombin Inhibition by Pyridin Derivatives |
Heteromer P09945; | 1×NAG; 2×NA; 1×PO4; 1×GOL; 1×02P; | ||||
| Assess | ||||||
| Thrombin-hirugen-gw420128 ternary complex at 1.39A resolution |
Heteromer P01050; | 1×NA; 1×CA; 1×897; | ||||
| Assess | ||||||
| Thrombin in complex with D-arginine (j77) |
Heteromer P09945; | 2×NA; 2×DMS; 1×PO4; 1×DAR; 1×NAG; | ||||
| Assess | ||||||
| X-ray structure of the human alpha-thrombin complex with a tripeptide phosphonate inhibitor. |
Heteromer P01050; | 1×PHW; | ||||
| Assess | ||||||
| Human Thrombin in complex with MI004 |
Heteromer P09945; | 1×NAG; 1×S04; 2×GOL; 1×PO4; 2×NA; | ||||
| Assess | ||||||
| Thrombin Inhibitor |
Heteromer P09945; | 1×GOL; 2×NA; 1×WX5; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in complex with 3-((5-(tert-butyl)isoxazol-3-yl)methyl)oxetan-3-amine (j54) |
Heteromer P09945; | 2×NA; 1×PO4; 1×NAG; 2×DMS; 1×D6Y; | ||||
| Assess | ||||||
| Human Thrombin In Complex With MI001 |
Heteromer P09945; | 1×NAG; 1×BJA; 1×PO4; 2×NA; | ||||
| Assess | ||||||
| Thrombin in Complex with a D-Phe-Pro-imidazole derivative |
Heteromer P09945; | 2×NA; 1×PO4; 1×DMS; 1×MJH; 1×NAG; | ||||
| Assess | ||||||
| Human Thrombin In Complex With MI340 |
Heteromer P09945; | 1×NAG; 1×M34; 1×PO4; 3×GOL; 2×NA; | ||||
| Assess | ||||||
| Thrombin in complex with (S)-N-(2-(aminomethyl)-5-chlorobenzyl)-1-((benzylsulfonyl)-D-arginyl)pyrro… |
Heteromer P09945; | 1×2TS; 1×NAG; 2×NA; 2×GOL; 1×DMS; | ||||
| Assess | ||||||
| Exploring Thrombin S1-pocket |
Heteromer P01050; | 2×NA; 1×53U; | ||||
| Assess | ||||||
| Human thrombin complexed with D-Phe-Pro-D-Arg-Ile |
Heteromer | 1×NAG; 1×NA; 1×IOD; 1×CL; 1×MPD; 1×MRD; | ||||
| Assess | ||||||
| Human Thrombin In Complex With MI353 |
Heteromer P09945; | 1×NAG; 2×TIF; 1×PO4; 2×NA; | ||||
| Assess | ||||||
| Human Thrombin in complex with MI329 |
Heteromer P09945; | 1×NAG; 2×S29; 1×PO4; 1×GOL; 2×NA; | ||||
| Assess | ||||||
| Human Thrombin In Complex With UBTHR97 |
Heteromer P09945; | 1×NAG; 1×P97; 1×PO4; 2×GOL; 2×NA; | ||||
| Assess | ||||||
| Thrombin Inhibition by Pyridin Derivatives |
Heteromer P09945; | 1×NAG; 1×10P; 1×GOL; 1×PO4; 2×NA; | ||||
| Assess | ||||||
| Human Thrombin in complex with MI331 |
Heteromer P09945; | 1×NAG; 1×M31; 2×GOL; 1×PO4; 2×NA; | ||||
| Assess | ||||||
| Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-… |
Heteromer P09945; | 2×NA; 1×UET; 1×PO4; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in Complex with a D-DiPhe-Pro-p-pyridine derivative |
Heteromer P09945; | 1×PO4; 2×NA; 1×DMS; 1×LXW; 1×NAG; | ||||
| Assess | ||||||
| Human Thrombin In Complex With UBTHR103 |
Heteromer P09945; | 1×NAG; 2×NA; 1×GOL; 1×PO4; 1×B03; | ||||
| Assess | ||||||
| Thrombin in Complex with a D-Phe-Pro-N-amidinopiperidine Derivative |
Heteromer P09945; | 1×DMS; 1×PO4; 2×NA; 1×NAG; 1×J3I; 1×TFA; | ||||
| Assess | ||||||
| Thrombin in complex with Inhibitor |
Heteromer P01050; | 2×NA; 1×22U; | ||||
| Assess | ||||||
| Human Thrombin in complex with MI332 |
Heteromer P09945; | 1×NAG; 1×M32; 2×GOL; 1×PO4; 2×NA; | ||||
| Assess | ||||||
| Human Thrombin In Complex With MI330 |
Heteromer P09945; | 1×NAG; 1×S33; 2×GOL; 1×PO4; 2×NA; | ||||
| Assess | ||||||
| Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-… |
Heteromer P09945; | 2×NA; 1×3ZD; 1×PO4; 1×NAG; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6… |
Heteromer P01050; | 1×APA; | ||||
| Assess | ||||||
| Disulfated madanin-thrombin complex |
Heteromer Q86FP9; | 1×NAG; 1×NA; | ||||
| Assess | ||||||
| Thrombin Inhibition by Pyridin Derivatives |
Heteromer P09945; | 1×NAG; 1×06P; 1×PO4; 1×GOL; 2×NA; | ||||
| Assess | ||||||
| Alpha-thrombin complex with sulfated hirudin (residues 54-65) and L- Arginine template inhibitor CS… |
Heteromer P09945; | 1×MIU; | ||||
| Assess | ||||||
| Thrombin Inhibition |
Heteromer P01050; | 1×26U; 2×NA; 1×BEN; | ||||
| Assess | ||||||
| Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-((1S)-2-((4- carbamimidoylphenyl)methylamin… |
Heteromer P09945; | 2×NA; 1×D6J; 1×PO4; 1×NAG; | ||||
| Assess | ||||||
| Human Thrombin in complex with MI328 |
Heteromer P09945; | 1×NAG; 1×S28; 1×PO4; 3×GOL; 2×NA; | ||||
| Assess | ||||||
| Exploring Thrombin S1 pocket |
Heteromer P01050; | 2×NA; 1×PO4; 1×37U; | ||||
| Assess | ||||||
| Exploring Thrombin S1 pocket |
Heteromer P01050; | 2×NA; 1×PO4; 1×32U; | ||||
| Assess | ||||||
| X-ray crystal structure of human alpha-thrombin with a tripeptide phosphonate inhibitor. |
Heteromer P01050; | 1×PHV; | ||||
| Assess | ||||||
| Thrombin Inhibition by Pyridin Derivatives |
Heteromer P09945; | 1×NAG; 2×NA; 1×GOL; 1×98P; | ||||
| Assess | ||||||
| Human Thrombin in complex with MI341 |
Heteromer P09945; | 1×NAG; 1×M41; 1×PO4; 2×GOL; 2×NA; | ||||
| Assess | ||||||
| Thrombin Inhibition |
Heteromer P01050; | 1×31U; 2×NA; | ||||
| Assess | ||||||
| SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN |
Heteromer P28504; | 1×NA; 1×132; | ||||
| Assess | ||||||
| Exploring thrombin S3 pocket |
Heteromer P09945; | 2×NA; 1×46U; 1×GOL; | ||||
| Assess | ||||||
| Novel Non-Covalent Thrombin Inhibitors Incorporating P1 4,5,6,7-Tetrahydrobenzothiazole Arginine Si… |
Heteromer P28504; | 2×NA; 1×165; | ||||
| Assess | ||||||
| Human Thrombin In Complex With UBTHR101 |
Heteromer P09945; | 1×NAG; 2×NA; 1×B01; | ||||
| Assess | ||||||
| HUMAN THROMBIN-INHIBITOR COMPLEX |
Heteromer P09945; | 1×NAG; 2×NA; 1×MEL; | ||||
| Assess | ||||||
| Thrombin Inhibition |
Heteromer P01050; | 2×NA; 1×27U; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and a pseudo-cyclic thrombin binding ap… |
Heteromer | 1×NAG; 1×0G6; 1×NA; 2×JL0; 2×JKR; 2×K; | ||||
| Assess | ||||||
| HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN |
Heteromer P09945; | 1×0ZE; 2×NA; | ||||
| Assess | ||||||
| KNOBLE Inhibitor |
Heteromer P01050; | 1×M18; 2×NA; | ||||
| Assess | ||||||
| Exploring Thrombin S1 Pocket |
Heteromer P01050; | 2×NA; 1×51U; | ||||
| Assess | ||||||
| Thrombin Inibition |
Heteromer P01050; | 2×NA; 1×19U; | ||||
| Assess | ||||||
| Thrombin in complex with 3-amidinophenylalanine inhibitor |
Heteromer P09945; | 1×NAG; 1×0NW; 2×NA; 1×PO4; 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of Thrombin in complex with macrocycle X1vE |
Heteromer | 1×NA; 1×X1V; | ||||
| Assess | ||||||
| STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR |
Heteromer P26631; | |||||
| Assess | ||||||
| Crystal structure of Thrombin in complex with macrocycle N14-PR4-A |
Heteromer | 1×NAG; 2×EDO; 1×MRQ; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of human thrombin mutant N143P in E* form |
Heteromer | 1×NAG; 4×GOL; | ||||
| Assess | ||||||
| Crystal structure of the thrombin mutant D221A/D222K |
Heteromer P28504; | 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of thrombin-variegin complex: Insights of a novel mechanism of inhibition and des… |
Heteromer P85800; | |||||
| Assess | ||||||
| Structural basis of thrombin-mediated factor V activation: essential role of the hirudin-like seque… |
Heteromer P12259; | 1×NAG; 1×BEN; 2×NA; 1×BGC; | ||||
| Assess | ||||||
| Crystal structure of Thrombin in complex with macrocycle T1 |
Heteromer | 1×NWF; | ||||
| Assess | ||||||
| Human thrombin - inhibitor complex |
Heteromer P28508; | 1×9MU; 1×NAG; | ||||
| Assess | ||||||
| Human thrombin - inhibitor complex |
Heteromer P28508; | 1×9MX; 1×NAG; 1×NA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND ALPHA-THROMBIN AT 2.6A |
Heteromer P07359; | 2×MES; 2×NAG; 2×DFP; | ||||
| Assess | ||||||
| Human thrombin - inhibitor complex |
Heteromer P28508; | 1×9MQ; 1×NAG; 1×NA; | ||||
| Assess | ||||||
| COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON NMR MODEL OF… |
Heteromer | 1×0G6; | ||||
| Assess | ||||||
| COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON X-RAY MODEL … |
Heteromer | 1×0G6; | ||||
| Assess | ||||||
| CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTI… |
Heteromer P28504; | 1×MIT; | ||||
| Assess | ||||||
| CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTI… |
Heteromer P28504; | 1×MID; | ||||
| Assess | ||||||
| Crystallographic analysis at 3.0-Angstroms resolution of the binding to human thrombin of four acti… |
Heteromer P28508; | 1×0G6; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and a pseudo-cyclic thrombin binding ap… |
Heteromer | 1×NAG; 1×0G6; 2×JL0; 2×JKR; 2×K; | ||||
| Assess | ||||||
| CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTI… |
Heteromer P28504; | 1×BEN; | ||||
| Assess | ||||||
| Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding mechanism |
Heteromer Q9NJS1; | 1×NAG; 1×NA; | ||||
| Assess | ||||||
| Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human ppack… |
Heteromer P00735; | 1×0G7; | ||||
| Assess | ||||||
| Human thrombin sandwiched between two DNA aptamers: HD22 and HD1-deltaT12 |
Heteromer | 1×NAG; 1×0G6; 3×NA; | ||||
| Assess | ||||||
| Thrombin in complex with benzamidine |
Heteromer P09945; | 1×NAG; 2×NA; 1×BEN; 1×PO4; 1×GOL; | ||||
| Assess | ||||||
| Thrombin in complex with 4-Methoxy-N-(2-pyridinyl)benzamide |
Heteromer P09945; | 1×NAG; 2×NA; 2×DMS; 1×SJR; 1×PO4; 3×GOL; 1×EDO; | ||||
| Assess | ||||||
| Human thrombin complexed with fragment-based small molecules occupying the S1 pocket |
Heteromer P09945; | 1×4CP; | ||||
| Assess | ||||||
| Human alpha-thrombin-Bivalirudin complex at PD5.0 |
Heteromer P28504; | 1×NAG; | ||||
| Assess | ||||||
| Thrombin in Complex with Benzylamine |
Heteromer P09945; | 2×NA; 2×ABN; 1×GOL; 1×PO4; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in complex with D-Phe-Pro-3-chloro-1,3-dihydroxybenzylamide derivative (13c) |
Heteromer P09945; | 2×NA; 2×DMS; 1×NAG; 1×PO4; 1×PRO; 1×OJK; | ||||
| Assess | ||||||
| Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(5-chloro-2-(hydroxymethyl)ben… |
Heteromer P09945; | 1×6TH; 1×NAG; 1×PO4; 1×DMS; 2×NA; 1×EDO; 3×GOL; | ||||
| Assess | ||||||
| Thrombin in Complex with Methylbenzylamine |
Heteromer P09945; | 2×NA; 1×02N; 1×PO4; 1×GOL; 1×NAG; | ||||
| Assess | ||||||
| Thrombin Mutant A190S in complex with (S) -1 - ((R) -2-amino-3,3-diphenylpropanoyl) -N- (3-chlorobe… |
Heteromer P09945; | 1×23U; 1×DMS; 1×PO4; 5×GOL; 2×NA; | ||||
| Assess | ||||||
| Human thrombin complexed with fragment-based small molecules occupying the S1 pocket |
Heteromer P09945; | 1×2CE; | ||||
| Assess | ||||||
| Thrombin in complex with fragment J02 |
Heteromer P09945; | 1×NAG; 2×DMS; 1×PO4; 2×NA; 1×F05; | ||||
| Assess | ||||||
| Thrombin in complex with 4-(((1-((2S)-1-((2R)-2-(benzylsulfonylamino)- 3-phenyl-propanoyl)pyrrolidi… |
Heteromer P09945; | 1×NAG; 2×NA; 2×GOL; 1×S49; 1×PO4; | ||||
| Assess | ||||||
| Thrombin Inhibition by Pyridin Derivatives |
Heteromer P09945; | 1×NAG; 1×99P; 1×PO4; 2×NA; | ||||
| Assess | ||||||
| Thrombin in complex with 5-chlorothiophene-2-sulfonamide (j94) |
Heteromer P09945; | 2×NA; 3×DMS; 1×PO4; 1×NAG; 1×8K2; 1×GOL; | ||||
| Assess | ||||||
| Thrombin in complex with MI2100 ((S)-N-(2-(aminomethyl)-5-chlorobenzyl)-1-((benzylsulfonyl)-L-argin… |
Heteromer P09945; | 1×NAG; 2×NA; 2×DMS; 1×EU5; | ||||
| Assess | ||||||
| Thrombin in complex with 2-amino-1-(4-bromophenyl)ethan-1-one (j10) |
Heteromer P09945; | 2×NA; 2×DMS; 2×47A; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in complex with 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide (j80) |
Heteromer P09945; | 2×NA; 2×DMS; 1×PO4; 1×08D; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in complex with 13k |
Heteromer P09945; | 2×NA; 1×PO4; 2×DMS; 2×GOL; 1×O5Z; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in complex with D-Phe-Pro-m-Trifluoromethylbenzylamide derivative (phe2) |
Heteromer P09945; | 2×NA; 1×DMS; 2×PO4; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in complex with 4-hydroxybenzamide (j89) |
Heteromer P09945; | 1×PO4; 2×NA; 1×NAG; 2×DMS; 1×HBD; | ||||
| Assess | ||||||
| Thrombin Inhibition |
Heteromer P01050; | 2×NA; 1×BEN; | ||||
| Assess | ||||||
| Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(2-(aminomethyl)-5-chlorobenzy… |
Heteromer P09945; | 1×NAG; 2×NA; 1×PO4; 1×GOL; 1×DMS; 1×71U; | ||||
| Assess | ||||||
| High affinity inhibitor of human thrombin |
Heteromer P01050; | 1×1TS; 2×NA; | ||||
| Assess | ||||||
| Structure of thrombin mutant delta(146-149e) in the free form |
Heteromer | 1×NAG; | ||||
| Assess | ||||||
| Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-… |
Heteromer P09945; | 2×NA; 1×6V2; 1×PO4; 1×NAG; | ||||
| Assess | ||||||
| Thrombin in Complex with a D-Phe-Pro-diaminopyridine derivative |
Heteromer P09945; | 2×DMS; 2×GOL; 2×NA; 1×NAG; 1×PO4; 1×GOZ; | ||||
| Assess | ||||||
| Thrombin in Complex with a D-Phe-Pro-2-bromothiophene Derivative |
Heteromer P09945; | 2×NA; 2×DMS; 1×GOL; 1×NAG; 1×MJK; | ||||
| Assess | ||||||
| Understanding Thrombin Inhibition |
Heteromer P01050; | 1×64U; 2×NA; | ||||
| Assess | ||||||
| Thrombin Inhibition |
Heteromer P01050; | 2×NA; 1×21U; | ||||
| Assess | ||||||
| Thrombin in complex with diphenyl ((4-carbamimidoylphenyl)((S)-1-((R)-3-cyclohexyl 2-((phenylmethyl… |
Heteromer P09945; | 1×MUZ; 1×NAG; 2×NA; 1×PO4; 2×DMS; | ||||
| Assess | ||||||
| Thrombin Mutant A190S in complex with (S)-1-(D-phenylalanyl)-N-(3-chlorobenzyl)pyrrolidine-2-carbox… |
Heteromer P09945; | 1×22U; 1×DMS; 1×PO4; 6×GOL; 2×NA; | ||||
| Assess | ||||||
| Human Thrombin Hirugen Inhibitor complex |
Heteromer P28507; | 1×701; 1×CA; 1×NA; | ||||
| Assess | ||||||
| Bisphenylic Thrombin Inhibitors |
Heteromer P01050; | 1×33U; 2×NA; | ||||
| Assess | ||||||
| Bisphenylic Thrombin Inhibitors |
Heteromer P01050; | 1×23U; 2×NA; | ||||
| Assess | ||||||
| Thrombin Inhibition |
Heteromer P09945; | 1×91U; 2×NA; | ||||
| Assess | ||||||
| Exploring thrombin S3 pocket |
Heteromer P09945; | 2×NA; 1×45U; 1×BEN; 1×GOL; | ||||
| Assess | ||||||
| ALPHA-THROMBIN COMPLEXED WITH HIRUGEN |
Heteromer P28507; | 1×MIN; | ||||
| Assess | ||||||
| Crystal structure of thrombin in complex with inhibitor |
Heteromer | 1×NA; 1×44U; | ||||
| Assess | ||||||
| Thrombin Inhibition |
Heteromer P01050; | 2×NA; 1×29U; | ||||
| Assess | ||||||
| Human thrombin-in complex with UB-THR11 |
Heteromer P09945; | 1×NAG; 1×11U; | ||||
| Assess | ||||||
| Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker |
Heteromer P09945; | 1×C2D; | ||||
| Assess | ||||||
| Crystal structure of sulfo-hirudin complexed to thrombin |
Heteromer P01050; | 1×NI; 1×NA; | ||||
| Assess | ||||||
| COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY |
Heteromer P01050; | 1×NA; 1×MDL; | ||||
| Assess | ||||||
| Thrombin in complex with (S)-N-(tert-butyl)-4-(3-(3-carbamimidoylphenyl)-2-((2',4'-dimethoxy-[1,1'-… |
Heteromer P09945; | 1×MUQ; 1×NAG; 2×NA; 1×DMS; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4 |
Heteromer P01050; | 1×NAG; 2×NA; 1×BZT; | ||||
| Assess | ||||||
| HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN |
Heteromer P09945; | 2×NA; 1×00L; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5-AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBI… |
Heteromer P01050; | 1×NAG; 2×NA; 1×BPP; | ||||
| Assess | ||||||
| THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES |
Heteromer P01050; | 2×NA; 1×0IV; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3 |
Heteromer P01050; | 1×NAG; 2×NA; 1×BT3; | ||||
| Assess | ||||||
| Thrombin inhibitors with rigid tripeptidyl aldehydes |
Heteromer P01050; | 2×NA; 1×0KV; | ||||
| Assess | ||||||
| Exploring thrombin S3 pocket |
Heteromer P09945; | 2×NA; 1×13U; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711. |
Heteromer | 2×NA; | ||||
| Assess | ||||||
| complex of human thrombin with XC-43 |
Heteromer A2IAB2; | 1×NAG; 1×NA; | ||||
| Assess | ||||||
| CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERE… |
Heteromer P01050; P28504; | 1×NAG; | ||||
| Assess | ||||||
| NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT |
Heteromer P01050; | 1×GR4; | ||||
| Assess | ||||||
| THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR |
Heteromer P09945; | 2×NA; 1×00N; | ||||
| Assess | ||||||
| Human Thrombin Hirugen Inhibitor complex |
Heteromer P28507; | 1×CA; 1×NA; 1×894; | ||||
| Assess | ||||||
| STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTOPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETI… |
Heteromer P01050; | 2×NA; 1×00P; | ||||
| Assess | ||||||
| Understanding Thrombin Inhibition |
Heteromer P01050; | 1×16U; 2×NA; | ||||
| Assess | ||||||
| CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXP… |
Heteromer P09945; | |||||
| Assess | ||||||
| STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBIT… |
Heteromer | 1×0G6; | ||||
| Assess | ||||||
| Human Thrombin Hirugen Inhibitor complex |
Heteromer P28507; | 1×CA; 1×NA; 1×895; | ||||
| Assess | ||||||
| Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to differe… |
Heteromer P09945; | 1×0G6; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of Thrombin in complex with macrocycle T3 |
Heteromer | 1×NAG; 1×NWR; 1×SO4; | ||||
| Assess | ||||||
| SELECTIVE NON-ELECTROPHILIC THROMBIN INHIBITORS |
Heteromer | 1×IH3; | ||||
| Assess | ||||||
| Crystal Structure of the W215A/E217A Mutant of Human Thrombin (space group P2(1)2(1)2(1)) |
Heteromer | |||||
| Assess | ||||||
| Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker |
Heteromer P09945; | 1×C1D; | ||||
| Assess | ||||||
| Crystal structure of the human thrombin mutant D102N in complex with the extracellular fragment of … |
Heteromer Q96RI0; | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2 |
Heteromer P01050; | 1×NAG; 2×NA; 1×BT2; | ||||
| Assess | ||||||
| Human thrombin sandwiched between two DNA aptamers: HD22 and HD1-deltaT3 |
Heteromer | 1×NAG; 1×0G6; 2×NA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1 |
Heteromer P01050; | 1×NAG; 2×NA; 1×BT1; | ||||
| Assess | ||||||
| CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXP… |
Heteromer P25116; | |||||
| Assess | ||||||
| Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker |
Heteromer P09945; | 1×5CB; | ||||
| Assess | ||||||
| X/N Joint refinement of Human alpha-thrombin-Bivalirudin complex PD5 |
Heteromer P28504; | 1×NAG; | ||||
| Assess | ||||||
| Complex of Recombinant Human Thrombin with a Designed Inhibitor |
Heteromer P09945; | 1×F25; 1×NA; 1×CA; | ||||
| Assess | ||||||
| Complex of recombinant human thrombin with an inhibitor |
Heteromer P28508; | 1×ESH; 1×NA; 1×CA; | ||||
| Assess | ||||||
| Complex of thrombin with designed inhibitor 7165 |
Heteromer P28504; | 1×SHY; 1×NA; 1×CA; | ||||
| Assess | ||||||
| Crystal Structure Analysis of thrombin in complex with compound D58 |
Heteromer P01050; | 1×NAG; 2×NA; 1×7R9; | ||||
| Assess | ||||||
| X-ray structure of the complex between human thrombin and the TBA deletion mutant lacking thymine 1… |
Heteromer | 1×0G6; 1×K; 1×NAG; 1×NA; | ||||
| Assess | ||||||
| Thrombin Inhibition |
Heteromer P01050; | 2×NA; 1×24U; 1×BEN; | ||||
| Assess | ||||||
| COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR |
Heteromer P28506; | 1×NA; 1×CA; 1×FSN; | ||||
| Assess | ||||||
| Crystal Structure of Thrombin in complex with compound51 |
Heteromer P28504; | 1×QQT; 1×NAG; | ||||
| Assess | ||||||
| Crystal Structure of Thrombin in complex with compound17 |
Heteromer P28504; | 1×N6H; 1×NAG; 1×DMS; | ||||
| Assess | ||||||
| Exploring thrombin S3 pocket |
Heteromer P09945; | 2×NA; 1×50U; | ||||
| Assess | ||||||
| Crystal Structure Analysis of thrombin in complex with compound D57, 5-Chlorothiophene-2-carboxylic… |
Heteromer P09945; | 1×NAG; 2×NA; 1×6XS; | ||||
| Assess | ||||||
| Thrombin Inhibitor Complex |
Heteromer P01050; | 1×UIB; | ||||
| Assess | ||||||
| Thrombin Inhibitor Complex |
Heteromer P01050; | 1×CCR; | ||||
| Assess | ||||||
| Complex of recombinant human thrombin with an inhibitor |
Heteromer P28508; | 1×348; 1×NA; 1×CA; | ||||
| Assess | ||||||
| Thrombin with 3-cycle no F |
Heteromer P28503; | 1×I25; 1×NA; 1×CA; | ||||
| Assess | ||||||
| Thrombin with 3-cycle with F |
Heteromer P01050; | 1×I26; 1×NA; 1×CA; | ||||
| Assess | ||||||
| Crystal Structure of Thrombin in complex with compound20a |
Heteromer P28504; | 1×QQ5; 1×NAG; | ||||
| Assess | ||||||
| Complex structure of human thrombin with N-methyl-arginine inhibitor |
Heteromer | |||||
| Assess | ||||||
| thrombin in complex with selective macrocyclic inhibitor at 1.8A |
Heteromer P28504; | 1×L86; | ||||
| Assess | ||||||
| Thrombin Inhibitor Complex |
Heteromer P01050; | 1×UIR; | ||||
| Assess | ||||||
| COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1 |
Heteromer P28504; | 1×T29; | ||||
| Assess | ||||||
| thrombin and P2 pyridine N-oxide inhibitor complex structure |
Heteromer P28504; | 1×L17; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR |
Heteromer P28504; | 1×PPX; | ||||
| Assess | ||||||
| Crystal Structure of Thrombin in complex with compound10 |
Heteromer P28504; | 1×QPW; 1×NAG; | ||||
| Assess | ||||||
| Thrombin Inhibitor Complex |
Heteromer P01050; | 2×NA; 1×UIP; 3×GOL; | ||||
| Assess | ||||||
| crystal structue of Thrombin in complex with a potent P1 heterocycle-Aryl based inhibitor |
Heteromer P28504; | 1×170; | ||||
| Assess | ||||||
| Crystal structure of thrombin in complex with a novel glucose-conjugated potent inhibitor |
Heteromer P09945; | 6×DMS; 1×2OJ; | ||||
| Assess | ||||||
| Crystal structure of thrombin in complex with inhibitor 15 |
Heteromer P28511; | 1×T15; | ||||
| Assess | ||||||
| X-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue RA-1008 |
Heteromer P01050; | 2×NA; 1×RA8; 2×GOL; | ||||
| Assess | ||||||
| X-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue RA-1014 |
Heteromer P01050; | 1×RA4; | ||||
| Assess | ||||||
| COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2 |
Heteromer P28504; | 1×T16; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR P… |
Heteromer P01050; | 1×T42; | ||||
| Assess | ||||||
| Human thrombin complexed with D-Phe-Pro-D-Arg-Cys |
Heteromer | 1×NAG; 1×NA; 1×IOD; 1×CL; 1×MPD; | ||||
| Assess | ||||||
| Thrombin in complex with inhibitor |
Heteromer P01050; | 1×NAG; 1×M6S; 2×NA; | ||||
| Assess | ||||||
| Thrombin in complex with inhibitor |
Heteromer P09945; | 1×NAG; 1×MVF; 2×NA; | ||||
| Assess | ||||||
| Thrombin in complex with inhibitor |
Heteromer P01050; | 1×NAG; 1×MM9; 2×NA; | ||||
| Assess | ||||||
| Thrombin in complex with inhibitor |
Heteromer P01050; | 1×NAG; 1×M4Z; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of thrombin in complex with compound 14b |
Heteromer P28504; | 1×177; | ||||
| Assess | ||||||
| Structure of thrombin in 400 mM potassium chloride |
Heteromer | 1×NDG; 1×K; | ||||
| Assess | ||||||
| Thrombin in complex with an azafluorenyl inhibitor 23b |
Heteromer P28504; | 1×062; | ||||
| Assess | ||||||
| Human thrombin complexed with Napsagatran, RO0466240 |
Heteromer P01050; | 2×NA; 1×N5N; 1×NAG; | ||||
| Assess | ||||||
| Crystal Structure of Thrombin in complex with compound42a |
Heteromer P28504; | 1×QQE; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of Thrombin in complex with compound30 |
Heteromer P28504; | 1×QQN; 1×NAG; | ||||
| Assess | ||||||
| Crystal Structure of Thrombin in complex with compound42b |
Heteromer P28504; | 1×NAG; 1×QQW; | ||||
| Assess | ||||||
| Thrombin in complex with inhibitor |
Heteromer P01050; | 1×NAG; 1×M67; 2×NA; | ||||
| Assess | ||||||
| Exploring thrombin S3 pocket |
Heteromer P09945; | 2×NA; 1×49U; 1×GOL; | ||||
| Assess | ||||||
| Crystal Structure of Thrombin in Complex with L-378,622 |
Heteromer P28504; | 1×CDA; | ||||
| Assess | ||||||
| Crystal Structure of Thrombin in complex with compound40 |
Heteromer P28504; | 1×QQK; 1×NAG; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR |
Heteromer | |||||
| Assess | ||||||
| STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTROPHILIC INHIBITORS HAVING CYCLOHEXYL MOIET… |
Heteromer P01050; | 2×NA; 1×00R; | ||||
| Assess | ||||||
| Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin |
Heteromer P28504; | 1×81A; | ||||
| Assess | ||||||
| Thrombin-Hirugen-L405,426 |
Heteromer P28504; | 1×CDD; | ||||
| Assess | ||||||
| Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin |
Heteromer P28504; | 1×14A; | ||||
| Assess | ||||||
| ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN |
Heteromer P01050; | 1×PRL; | ||||
| Assess | ||||||
| thrombin-hirugen_l-378,650 |
Heteromer P28506; | 1×CDB; | ||||
| Assess | ||||||
| INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-… |
Heteromer | 1×NA; | ||||
| Assess | ||||||
| Human alpha-thrombin complexed with a peptidyl pyridinium methyl ketone containing bivalent inhibit… |
Heteromer | |||||
| Assess | ||||||
| thrombin in complex with selective macrocyclic inhibitor |
Heteromer P28504; | 1×T76; | ||||
| Assess | ||||||
| Exploring thrombin S3 pocket |
Heteromer P09945; | 2×NA; 1×12U; | ||||
| Assess | ||||||
| STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE |
Heteromer | 1×0G6; | ||||
| Assess | ||||||
| 2-(2-Chloro-6-Fluorophenyl)Acetamides as Potent Thrombin Inhibitors |
Heteromer P09945; | 1×I50; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2… |
Heteromer P28507; | 1×T19; | ||||
| Assess | ||||||
| THROMBIN COMPLEXED WITH HIRUGEN AND A BETA-STRAND MIMETIC INHIBITOR |
Heteromer P09945; | 2×NA; 1×00K; | ||||
| Assess | ||||||
| D-Phe-Pro-Arg-Type Thrombin Inhibitor |
Heteromer | 1×162; | ||||
| Assess | ||||||
| Cyanofluorophenylacetamides as Orally Efficacious Thrombin Inhibitors |
Heteromer P28504; | 1×DKK; | ||||
| Assess | ||||||
| thrombin in complex with an oxazolopyridine inhibitor 21 |
Heteromer P01050; | 1×382; | ||||
| Assess | ||||||
| Thrombin in complex with an oxazolopyridine inhibitor 2 |
Heteromer P01050; | 1×501; | ||||
| Assess | ||||||
| Discovery and Clinical Evaluation of RWJ-671818, a Thrombin Inhibitor with an Oxyguanidine P1 Motif |
Heteromer P01050; | 1×NLI; | ||||
| Assess | ||||||
| Crystal structure of human thrombin bound to ppack with tryptophans replaced by 5-F-tryptophan |
Heteromer | 2×NA; 1×0G6; | ||||
| Assess | ||||||
| Crystal structure of Thrombin bound to P2 macrocycle |
Heteromer | 1×ODB; 1×NAG; 3×EDO; 1×NA; | ||||
| Assess | ||||||
| HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N-[5-(AMINOIMINOMETHYL)AMINO]-1-{{BENZOTHIA… |
Heteromer P09945; | 1×00Q; 2×NA; | ||||
| Assess | ||||||
| Nonbasic Thrombin Inhibitor Complex |
Heteromer P01050; | 1×GAH; | ||||
| Assess | ||||||
| Crystal structure of thrombin in complex with compound 1 |
Heteromer P28504; | 1×176; | ||||
| Assess | ||||||
| Human thrombin-in complex with UB-THR10 |
Heteromer P09945; | 1×NAG; 2×NA; 1×10U; | ||||
| Assess | ||||||
| Crystallographic structures of Thrombin complexed with Thrombin receptor peptides: Existence of exp… |
Heteromer P25116; | 1×0G6; | ||||
| Assess | ||||||
| orally active thrombin inhibitors |
Heteromer | 1×34P; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and a pseudo-cyclic thrombin binding ap… |
Heteromer | 1×0G6; 1×NA; 1×JL0; 1×JKR; 1×K; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-1-(AMINOIMINOMETHYL)-N-[[1-[N-[(2-NAPHTHALENYLSULFO… |
Heteromer P01050; | 1×BM9; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and a duplex/quadruplex 31-mer DNA apta… |
Heteromer | 1×0G6; 1×K; | ||||
| Assess | ||||||
| CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXP… |
Heteromer P25116; | |||||
| Assess | ||||||
| thrombin in complex with inhibitor |
Heteromer P01050; | 1×NA; 1×UNB; | ||||
| Assess | ||||||
| Thrombin in complex with Benzothiazole Guanidine |
Heteromer | 1×MKY; 1×NA; 1×ACT; | ||||
| Assess | ||||||
| Human thrombin chimera with human residues 184a, 186, 186a, 186b, 186c and 222 replaced by murine t… |
Heteromer | 1×0G6; 1×NAG; | ||||
| Assess | ||||||
| High-salt crystal structure of a thrombin-GpIbalpha peptide complex |
Heteromer P07359; | 1×NA; 1×0G6; 1×GOL; | ||||
| Assess | ||||||
| HUMAN THROMBIN-INHIBITOR COMPLEX |
Heteromer P09945; | 1×NAG; 2×NA; 1×IGN; | ||||
| Assess | ||||||
| Crystal structure of thrombin in complex with a novel glucose-conjugated potent inhibitor |
Heteromer P09945; | 6×DMS; 1×2FN; | ||||
| Assess | ||||||
| Thrombin in complex with inhibitor |
Heteromer P01050; | 1×NA; 1×SN3; | ||||
| Assess | ||||||
| Thrombin in complex with natural product inhibitor Oscillarin |
Heteromer P28504; | 1×NAG; 2×NA; 1×OSC; | ||||
| Assess | ||||||
| STRUCTURE OF HUMAN ALPHA-THROMBIN Y225I MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE |
Heteromer | |||||
| Assess | ||||||
| STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE |
Heteromer | 1×0G6; 1×NA; | ||||
| Assess | ||||||
| STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR |
Heteromer P00974; | |||||
| Assess | ||||||
| CRYSTALLOGRAPHIC STRUCTURE OF HUMAN GAMMA-THROMBIN |
Heteromer | |||||
| Assess | ||||||
| Thrombin in complex with inhibitor |
Heteromer P28504; | 1×NA; 1×G44; | ||||
| Assess | ||||||
| THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN |
Heteromer P07204; | 2×0G6; | ||||
| Assess | ||||||
| Thrombin Inhibitor |
Heteromer P01050; | 1×2TS; 2×NA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURES OF THROMBIN WITH THIAZOLE-CONTAINING INHIBITORS: PROBES OF THE S1' BINDING SITE |
Heteromer P09945; | 2×NA; 1×QWE; | ||||
| Assess | ||||||
| Specifity for Plasminogen Activator Inhibitor-1 |
Heteromer P01050; | |||||
| Assess | ||||||
| SERINE PROTEASE |
Heteromer P01050; | 2×RB; | ||||
| Assess | ||||||
| HUMAN THROMBIN COMPLEX WITH HIRUDIN VARIANT |
Heteromer P01050; | |||||
| Assess | ||||||
| ACTIVE SITE MIMETIC INHIBITION OF THROMBIN |
Heteromer P28504; | 1×0ZI; | ||||
| Assess | ||||||
| Tsetse thrombin inhibitor in complex with human alpha-thrombin - acid-stable sulfotyrosine analogue |
Heteromer O97373; | 1×NAG; 1×NA; | ||||
| Assess | ||||||
| CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXP… |
Heteromer P25116; | |||||
| Assess | ||||||
| CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXP… |
Heteromer P25116; | |||||
| Assess | ||||||
| Cryo-EM structure of POmAb, a Type-I anti-prothrombin antiphospholipid antibody, bound to kringle-1… |
Heteromer | |||||
| Assess | ||||||
| 1.9 angstrom crystal structure of wild-type human thrombin in the sodium free state | homo-4-mer | 7×GOL; | ||||
| Assess | ||||||
| Crystal structure of human thrombin mutant W215A | homo-4-mer | 2×ZN; 2×NAG; | ||||
| Assess | ||||||
| Crystal structure of the potent anticoagulant thrombin mutant W215A/E217A in free form | homo-4-mer | |||||
| Assess | ||||||
| Crystal Structure of Prethombin-2/Fragment-2 Complex | homo-2-mer | 2×BU1; | ||||
| Assess | ||||||
| Crystal structure of human meizothrombin desF1 | homo-2-mer | 1×NAG; 1×SO4; 1×DFK; 1×NA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN MEIZOTHROMBIN DESF1 MUTANT S195A bound with PPACK | homo-2-mer | 1×NAG; 2×ZN; 1×0G6; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of the slow form of thrombin in a self_inhibited conformation | homo-2-mer | 1×NAG; 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of the anticoagulant thrombin mutant W215A/E217A bound to PPACK | homo-2-mer | 3×ZN; 1×0G6; 1×NAG; | ||||
| Assess | ||||||
| HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPL… | homo-2-mer | 1×NAG; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and NU172, a duplex/quadruplex 26-mer D… | homo-2-mer | 1×NAG; 1×0G6; 1×NA; 1×K; 1×GOL; | ||||
| Assess | ||||||
| THE CRYSTAL STRUCTURE OF ALPHA-THROMBIN-HIRUNORM IV COMPLEX REVEALS A NOVEL SPECIFICITY SITE RECOGN… | homo-2-mer | 1×NAG; | ||||
| Assess | ||||||
| NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT | homo-2-mer | 1×GR3; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and NU172, a duplex/quadruplex 26-mer D… | homo-2-mer | 1×NAG; 1×0G6; 2×NA; 1×GOL; | ||||
| Assess | ||||||
| Inhibitor-free human thrombin mutant C191A-C220A | homo-2-mer | 1×NAG; 2×SO4; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha-thrombin and modified 15-mer DNA aptamer contain… | homo-2-mer | 1×K; 1×0G6; 1×NA; 1×NAG; | ||||
| Assess | ||||||
| COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN | homo-2-mer | |||||
| Assess | ||||||
| Ternary complex of an orally active thrombin inhibitor with human thrombin and a c-terminal hirudin… | homo-2-mer | 1×CDO; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha-thrombin and modified 15-mer DNA aptamer contain… | homo-2-mer | 1×K; 1×0G6; 1×NA; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of the slow form of thrombin in a self-inhibited conformation | homo-2-mer | 1×EPE; | ||||
| Assess | ||||||
| Crystal structure of thrombin mutant E14eA/D14lA/E18A/S195A | homo-2-mer | 1×NA; | ||||
| Assess | ||||||
| Crystal structure of the anticoagulant slow form of thrombin | homo-2-mer | 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of human alpha-thrombin in complex with suramin | homo-2-mer | 1×SVR; | ||||
| Assess | ||||||
| Unliganded wild-type human thrombin | homo-2-mer | 1×NAG; 1×BCN; 1×NA; 1×IOD; 1×CL; 2×MRD; 1×MPD; | ||||
| Assess | ||||||
| Structure of thrombin mutant Y225P in the E form | homo-2-mer | 1×K; 1×TRS; | ||||
| Assess | ||||||
| Slow form of Thrombin Bound with PPACK | homo-2-mer | 1×0G6; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and a thrombin binding aptamer variant … | homo-2-mer | 1×0G6; 1×NA; 1×K; | ||||
| Assess | ||||||
| Fast form of thrombin mutant R(77a)A bound to PPACK | homo-2-mer | 1×0G6; 1×NAG; 1×NA; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and thrombin binding aptamer in the pre… | homo-2-mer | 2×ZN; 1×0G6; 1×NAG; 1×NA; 2×CL; 1×K; | ||||
| Assess | ||||||
| Structure of thrombin mutant S195a bound to the active site inhibitor argatroban | homo-2-mer | 1×NA; 1×15U; | ||||
| Assess | ||||||
| Crystal Structure of Human Alpha Thrombin in Complex with a 27-mer Aptamer Bound to Exosite II | homo-2-mer | 1×0G6; 1×NA; 1×NAG; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and two duplex/quadruplex aptamers: NU1… | homo-2-mer | 1×0G6; 1×NAG; 2×NA; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and a thrombin binding aptamer variant … | homo-2-mer | 1×0G6; 1×NA; 1×K; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and thrombin binding aptamer in the pre… | homo-2-mer | 3×ZN; 1×0G6; 1×NAG; 2×NA; 2×CL; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROARG-OH | homo-2-mer | 1×DP7; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770. | homo-2-mer | 2×NA; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-N-BUTYL-AMIDINO-GLYCINE-OH | homo-2-mer | 1×DI3; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROORNITHINE-OH | homo-2-mer | 1×DI5; | ||||
| Assess | ||||||
| Crystal structure of the procoagulant fast form of thrombin | homo-2-mer | 1×NAG; 1×NA; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROLYS-OH | homo-2-mer | 1×DI2; | ||||
| Assess | ||||||
| HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-HOMOLYS-OH | homo-2-mer | 1×DI4; | ||||
| Assess | ||||||
| Reversible Covalent Direct Thrombin Inhibitors | homo-2-mer | 1×71F; 1×NAG; 1×NA; | ||||
| Assess | ||||||
| Structure of thrombin mutant Y225P in the E* form | homo-2-mer | 1×NAG; 2×GOL; | ||||
| Assess | ||||||
| X-ray structure of the complex between human alpha thrombin and a thrombin binding aptamer variant … | homo-2-mer | 1×0G6; 1×NA; 1×K; | ||||
| Assess | ||||||
| BOVINE THROMBIN--BM51.1011 COMPLEX | homo-2-mer | 1×I11; | ||||
| Assess | ||||||
| Crystal structure of prothrombin deletion mutant residues 154-167 ( Form I ) | monomer | 2×NAG; 6×MG; 1×NAG; 9×SO4; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of Ca2+ bound prothrombin deletion mutant residues 146-167 | monomer | 5×CA; 3×NAG; | ||||
| Assess | ||||||
| Crystal structure of human prothrombin mutant S101C/A470C | monomer | 1×NAG; 6×MG; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of prothrombin mutant S101C/A470C | monomer | 1×NAG; 6×MG; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of prothrombin deletion mutant residues 146-167 ( Form II ). | monomer | 1×NAG; 2×NAG; 4×MG; | ||||
| Assess | ||||||
| Crystal structure of Ca2+-free prothrombin deletion mutant residues 146-167 | monomer | 3×NAG; | ||||
| Assess | ||||||
| Crystal structure of human prethrombin-1 | monomer | 1×NAG; 2×TRS; 2×GOL; | ||||
| Assess | ||||||
| Structure of recombinant Gla-domainless prothrombin mutant S525A | monomer | 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of prethrombin-2 mutant E14eA/D14lA/E18A/S195A | monomer | 7×PO4; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL BICYCLIC LACTAM INHIBITOR | monomer | 1×BLI; | ||||
| Assess | ||||||
| Crystal structure of human prethrombin-2 with tryptophans replaced by 5-F-tryptophan | monomer | 1×GOL; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of prethrombin-2 mutant S195A in the the open form | monomer | |||||
| Assess | ||||||
| Structure of prethrombin-2 mutant s195a bound to the active site inhibitor argatroban | monomer | 1×15U; | ||||
| Assess | ||||||
| Crystal structure of prethrombin-2 mutant S195A in the alternative form | monomer | 2×GOL; | ||||
| Assess | ||||||
| Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures | monomer | |||||
| Assess | ||||||
| Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures | monomer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH BCH-10556 AND EXOSITE-DIRECTED PEPTIDE | monomer | 1×110; | ||||
| Assess | ||||||
| Crystal structure of the anticoagulant slow form of thrombin | monomer | 1×NAG; | ||||
| Assess | ||||||
| Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold … | monomer | |||||
| Assess | ||||||
| HVF18 in complex with LPS micelles | monomer | |||||
| Assess | ||||||
| VFR12 in complex with LPS micelles | monomer | |||||
| Assess | ||||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 5edm.1.A | monomer | 0.73 | 1×MG; | 98.40 | ||
| Assess | ||||||
| 6c2w.1.A | monomer | 0.60 | 2×MG; | 99.48 | ||
| Assess | ||||||